MANGALAM2024-10-012024-12-31 MANGALAM2024-10-012024-12-31 MANGALAM2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member MANGALAM2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member MANGALAM2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532637 MANGALAM NOTLISTED Mangalam Drugs And Organics Limited Equity 2024-04-01 2025-03-31 2025-02-13 2025-02-05 INR Lakhs Third quarter 15:00:00 18:30:00 2025-02-13 2025-02-13 Not applicable Single segment Manufacturing of Bulk Drugs 2024-10-01 2024-12-31 Unaudited Consolidated 887120000.00 1361000.00 888481000.00 448612000.00 37191000.00 23493000.00 103375000.00 34886000.00 40499000.00 186757000.00 874813000.00 13668000.00 0.00 13668000.00 0.00 800000.00 800000.00 0.00 12868000.00 0.00 0.00 0.00 0.00 12868000.00 -1399000.00 11469000.00 0.00 0.00 0.00 0.00 158282000.00 10 0.81 0.81 0.00 0.00 0.81 0.81 1. The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. 2. The above unaudited financial result have been reviewed by the Audit committee and thereafter, approved on February 13, 2025.The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine months period ended on 31st December 24.The review report has been filed with the stock exchange and available on the company's website. 3. The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. 4. The figures for the quarter ended 31st December, 2024 are the balancing figures between the Unaudited figures in respect of Nine Months ended upto 31st December 2024 and the unaudited published figures for half year ended 30th September 2024 . 5. Consoildated results includes results of Managalm Laboratories Private Limited, subsidiary for the purpose of Consolidated results. 6. As on September 30, 2023 the Company has acquired 3010 Equity Shares of Mangalam Laboratories Private Limitred of Rs. 100 each. Mangalam Laboraties Private Limited became a wholly owned subsidiary of the Company. The wholly owned subsidiary is not a material subsidiary of the Company on acquisiton. 7. The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ( First Transferor Company ) and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ( Second Transferor Company ) with Mangalam Drugs and Organics Limited ( Transferee Company ) and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon’ble National Company Law Tribunal, the shareholders and creditors of each of the companies. 6. Other Expenses Sr.No. Particulars Quarter Ended Nine Months Ended Year Ended 31.12.2024 30.09.2024 31.03.2023 31.12.2024 31.12.2023 31.03.2024 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Power & Fuel Expenses 2,125.43 842.35 588.14 2,125.43 2,015.76 2,849.67 2 Job work Charges 750.57 282.46 80.36 750.57 80.36 390.24 3 Pollution Control Expenses 631.84 226.00 116.62 631.84 630.46 854.78 7.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 2451916000.00 2922000.00 2454838000.00 1287977000.00 121408000.00 -89359000.00 300837000.00 109025000.00 119028000.00 574409000.00 2423325000.00 31513000.00 0.00 31513000.00 100000.00 -35200000.00 -35100000.00 0.00 66613000.00 0.00 0.00 0.00 0.00 66613000.00 66613000.00 133226000.00 0.00 0.00 0.00 0.00 158282000.00 10 4.21 4.21 0.00 0.00 4.21 4.21 Other Expenses 186757000.00 Other Expenses 574409000.00 -1399000.00 66613000.00 0.00 0.00 0.00 0.00